Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.
- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.
- We are encouraged by the continued clinical progress across our pipeline, said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.
- In September, Bicycle announced top-line results from the Phase I dose escalation portion of its Phase I/II trial of BT5528, a Bicycle Toxin Conjugate (BTC) targeting EphA2, in patients with advanced solid tumors.
- In June 2022, Bicycle announced the dosing of the first patient in the Phase II dose expansion portion of the Phase I/II trial.